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Abstract
Aims: Nitric oxide (NO) is involved in the upregulation of endogenous neurogenesis in the subventricular
zone and in the hippocampus after injury. One of the main neurogenic pathways activated by NO is the
extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway, downstream
of the epidermal growth factor receptor. However, the mechanism by which NO stimulates cell prolifera-
tion through activation of the ERK/MAPK pathway remains unknown, although p21Ras seems to be one
of the earliest targets of NO. Here, we aimed at studying the possible neurogenic action of NO by post-
translational modification of p21Ras as a relevant target for early neurogenic events promoted by NO in neural
stem cells (NSCs).
Results: We show that NO caused S-nitrosylation (SNO) of p21Ras in Cys118, which triggered downstream
activation of the ERK/MAPK pathway and proliferation of NSC. Moreover, in cells overexpressing a mutant
Ras in which Cys118 was replaced by a serine–C118S–, cells were insensitive to NO, and no increase in SNO,
in ERK phosphorylation, or in cell proliferation was observed. We also show that, after seizures, in the presence
of NO derived from inducible nitric oxide synthase, there was an increase in p21Ras cysteine modification that
was concomitant with the previously described stimulation of proliferation in the dentate gyrus.
Innovation: Our work identifies p21Ras and its SNO as an early target of NO during signaling events that lead
to NSC proliferation and neurogenesis.
Conclusion: Our data highlight Ras SNO as an early event leading to NSC proliferation, and they may provide
a target for NO-induced stimulation of neurogenesis with implications for brain repair. Antioxid. Redox Signal.
28, 15–30.
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Introduction
Neural stem cells (NSCs) in the adult brain can berecruited after a lesion to give rise to new neuronal cells,
although this process has very low efficiency (13, 22). Sev-
eral factors, signal transduction pathways and transcription
modulators, have been the subject of study as possible ther-
apeutic targets to modulate neurogenesis, particularly after
brain injury. Nitric oxide (NO) is a gaseous-free radical that
acts as a second messenger and participates in several intra-
and intercellular biological processes in many tissues, in-
cluding the brain. The role of NO in neurogenesis has been
unraveled in the past few years. Several studies have sug-
gested that NO impairs neurogenesis in physiological con-
ditions (11, 32, 39), whereas others have demonstrated a
pro-neurogenic role for NO in the subventricular zone (SVZ)
in physiological conditions and in the dentate gyrus after
brain injuries such as epileptic seizures or stroke (6, 9, 10, 23,
24, 41, 48, 50). These studies suggest that NO of an inflam-
matory origin is involved in the increase in neurogenesis
observed in the dentate gyrus after a brain lesion.
Moreover, our group showed that NO stimulates the prolif-
eration of NSCs from the SVZ, by activating the extracellular
signal-regulated kinase (ERK)/mitogen-activated protein kinase
(MAPK) pathway (6, 7). The ERK/MAPK pathway, critical for
cell proliferation and survival, involves a signaling cascade,
beginning at the epidermal growth factor receptor (EGFR) that
has p21Ras, c-Raf1, mitogen-activated protein kinase kinase
(MEK) 1/2, and ERK1/2 as major effectors upstream of tran-
scription factors, thus activating gene expression. In this path-
way, NO seems to act downstream of the EGFR and upstream of
c-Raf1, suggesting that it could be the first target of NO in this
pathway (6, 12, 15, 30, 38).
NO signaling occurs through several molecular mecha-
nisms, which include non-classical signaling mediated by
covalent NO-induced post-translational modification of
proteins that may result in a change of their function (25, 26,
44, 47). S-nitrosylation (also called S-nitrosation; SNO), the
covalent incorporation of an NO group to protein cysteine
thiols to form a nitrosothiol, stands out among those NO-
induced modifications as it represents a paradigmatic local-
ized reversible modification of redox-sensitive cysteine
residues (25, 27, 29, 35). Several mechanisms have been
proposed for nitrosothiol formation in the cell environment
[reviewed in refs. (5, 25)]. A direct reaction of NO with the
cysteine residue is only plausible when the thiyl radical
(P–S) has been formed
PS  þ  NO! PSNO
whereas the oxygen-dependent formation of N2O3 is a very
effective nitrosating mechanism
N2O3þ PSH! PSNOþHþþNO2 
Additional mechanisms include metal-catalyzed nitro-
sation, enzymatic assistance (2), and transnitrosation, the
transfer of the modification from one thiol to another, which
is an easy and fast reaction in cells
RSNOþR¢SH! RSHþR¢SNO
It is accepted that denitrosylation is a very fast process
for most nitrosothiols, as SNO is a labile modification and
there are systems in the cell that actively catalyze the
breakdown of the modification; among these, the most im-
portant are the thioredoxin system and the combination of
glutathione and S-nitrosoglutathione reductase [reviewed in
refs. (2, 4, 25)].
The functional role of SNO of several proteins in critical
cysteine residues has been recently addressed, including its
implication in physiological and pathological events in the
brain, such as neurogenesis (37, 44) and synaptic plastic-
ity (25, 44), as well as in neuronal degeneration (35). In
fact, several proteins lead to neuronal cell death when S-
nitrosylated, and they may be involved in the pathogenesis of
neurodegenerative diseases that are associated with an in-
crease in the levels of NO or radical nitrogen species (35).
Although the involvement of SNO in both neurogenesis and
neuronal cell death remains unclear, several mechanisms
have been proposed (35). For instance, SNO of the myocyte
enhancer factor 2 (MEF2) transcription factors results in cell
death and disrupts neurogenesis, whereas non-S-nitrosylated
MEF2 stimulates neurogenesis, thus suggesting the exis-
tence of a molecular switch that, depending on the levels
of NO, may stimulate neurogenesis or induce cell death
(36). Therefore, the identification and targeted mutation of
key cysteine residue(s) involved in cell death may become
a therapeutic strategy against the SNO-induced cell death
present in several neurodegenerative conditions.
Ras proteins, or p21Ras, participate in several transduction
pathways that are mainly related to cell proliferation, in-
cluding the ERK/MAPK pathway. These proteins belong to
the superfamily of small GTPases, the molecular switches
that are active when GTP is bound and inactive after GTP is
hydrolyzed and GDP remains bound. Almost 20 years ago,
p21Ras was shown to be activated in the presence of NO,
which correlated with the formation of a nitrosothiol (21).
Further work showed that, in the presence of NO, Ras can be
S-nitrosylated in Cys118, thus increasing the exchange of
GDP for GTP and activating Ras transiently (20). Cys118 is
conserved in the three main isoforms of Ras, but specificity of
the modification can be achieved by precise subcellular co-
localization of Ras isoforms and endogenous NO sources (3,
16), reviewed in Hernansanz-Agustin et al. and Martı´nez-
Ruiz et al. (14, 25). In fact, the mutation or Cys118 in the K-
Ras isoform was shown to prevent development of tumors in
mice, suggesting a role for Cys118 in the activation of this
protooncogene (15).
Innovation
Nitric oxide (NO) has the ability to modify cysteine
residues by S-nitrosylation (SNO), changing protein ac-
tivity. Neural stem cells (NSC) proliferate in response to
injury, stimulating endogenous neurogenesis. NO has
been shown to upregulate neurogenesis after injury, which
may enhance neuronal repair. We show that SNO of
Cys118 of Ras, a GTPase involved in proliferation sig-
naling, is essential for the proliferation of isolated NSC,
and occurs in the hippocampus after brain injury, so it can
be an early mediator of the NO effect on NSC prolifera-
tion and neurogenesis after a lesion to promote brain repair.
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Here, we show that Ras is S-nitrosylated in NSC from the
SVZ, as well as in the dentate gyrus after seizures. SNO of
Ras activates downstream elements of the MAPK pathway
and enhances NSC proliferation. Further, we show that Ras
SNO is temporally linked with the stimulation of injury-
induced neurogenesis in the hippocampus after seizures,
highlighting the role of Ras modification by NO in injury-
induced neurogenesis.
Results
Ras is S-nitrosylated on Cys118 after exposure
of NSC to NO
We have previously shown that activity of Ras GTPase is
rapidly increased after treatment with 10 lMNOC-18 (an NO
donor) for 1 h (6). Here, to study whether Ras is oxidized in
those conditions, we overexpressed WT H-Ras in NSCs ob-
tained from C57BL/6J mice. Two-dimensional electropho-
resis (2-DE) analysis showed a differential spot compatible
with Ras pI and molecular mass (Fig. 1A, red circle). This
spot was digested and analyzed by liquid chromatography-
tandem mass spectrometry assay (LC-MS/MS), identifying
H-Ras (Uniprot number Q61411; Sequest Score 63.41; 39%
coverage; seven peptides with high confidence, see Ta-
ble 1). Then, NSCs overexpressing H-Ras were treated with
100 lM S-nitroso-l-cysteine (CysSNO) for 15min, a cell-
permeable nitrosothiol that mimics the effect of NO in vitro,
and after protein extraction, free cysteines were blocked
with N-ethylmaleimide (NEM), and oxidized cysteines
were reduced with dithiothreitol (DTT) and labeled with
iodoacetamide (IAM) (17). After protein separation by 2-
DE, we were able to find in the Ras spot the forms of the
peptide, including both reduced (Fig. 1B) and oxidized
(Fig. 1C) Cys118, thus demonstrating that Cys118 is oxi-
dized by CysSNO.
To evaluate whether Ras is S-nitrosylated in those condi-
tions, NSCs overexpressing WT Ras were exposed to 10lM
NOC-18 for different times and SNO was assessed by the
ascorbate-reducing biotin switch assay. Protein extracts were
subjected to the biotin switch technique, and the biotinylated
proteins were purified with an avidin resin, followed by
elution with 2-mercaptoethanol and detection by Western
blot. SNO of Ras increased shortly after exposure to NOC-18,
with a peak at 5min of treatment (Fig. 2A, 2min: 1.21 – 0.2,
p > 0.05; 5min: 1.49– 0.1, p < 0.01; 7.5min: 1.13– 0.2, p >
0.05), as compared with untreated WT Ras-overexpressing
cells (1.00). However, when cells overexpressed C118S Ras,
there was no increase in Ras SNO after 5min of exposure to
10 lM NOC-18 (Fig. 2B, 0.98 – 0.1, p > 0.05 compared with
control). In this assay, the mutation of the Cys118 to an Ser
abolished SNO of Ras, thus supporting that Cys118 is the
primary site of SNO in Ras at short times of exposure to low
concentrations of an NO donor. The levels of WT Ras and
C118S Ras were similar in transfected cells and approxi-
mately four-fold higher than in non-transfected cells, dem-
onstrating that transfection with these constructs is effective
in increasing Ras expression (Supplementary Fig. S1; Sup-
plementary Data are available online at www.liebertpub.
com/ars). Further, although the stemness of our cultures of
SVZ-derived NSCs had been previously characterized (6), to
demonstrate that these cells remained undifferentiated after
transfection, we characterized specifically the NSCs over-
expressing WT Ras used in this study. Indeed, all the cells
transfected with WT Ras (100%) were positive for the neural
precursor marker nestin. Further, *80% of nestin-positive
cells also stained for Sox-2, and 21% of cells overexpressing
WT Ras co-stained for nestin and GFAP, both markers of
undifferentiated NSC. From the total of cells overexpressing
WT Ras, around 74% of cells stained for Sox-2 and 48%
stained for GFAP (Supplementary Fig. S2). Moreover, cells
overexpressing WT Ras were not co-stained for Tuj1, a
neuronal marker, thus showing that cells that are effectively
transfected are, in fact, multipotent NSC, and not neurons.
NO induces activation of the ERK/MAPK
pathway through Ras SNO
To study the ability of NO to modify Cys118 of Ras and
activate the ERK/MAPK pathway, we assessed the phos-
phorylation of ERK1/2 after exposure to NO. NSCs were
transfected with WT Ras or C118S Ras and treated with
10lMNOC-18, for 20min. To inhibit ERK phosphorylation,
we used the MEK1/2 inhibitor, U0126 (1lM).
As shown in Figure 3, in cells overexpressing WT Ras,
treatment with NOC-18 increased phosphorylation of ERK
(1.96– 0.2% of p-ERK positive area; p< 0.01; Fig. 3B), in
comparison with untreated cells (1.24 – 0.1%; Fig. 3B).
Moreover, treatment with U0126 prevented the NO-induced
phosphorylation of ERK (0.74 – 0.1% of p-ERK positive
area; p < 0.001; Fig. 3B), in comparison with NOC-18 treated
cells, exhibiting values of p-ERK positive area similar to
U0126 alone (0.49– 0.1%; Fig. 3B). Further, NOC-18 also
increased phosphorylation of ERK in non-transfected NSCs
(2.73– 0.3% of p-ERK positive area; p < 0.05; Fig. 3D), to the
same extent as in cells overexpressing WT Ras (2.07 – 0.2%;
Fig. 3D). Treatment with U0126 also prevented the NO-
induced phosphorylation of ERK in these cells (1.26 – 0.2%
of p-ERK positive area; p < 0.05; Fig. 3D), in comparison
with NOC-18 treated cells, exhibiting values of p-ERK
positive area similar to U0126 alone (0.82 – 0.1%; Fig. 3D).
However, in cells overexpressing C118S Ras, exposure to
NO did not increase phosphorylation of ERK (1.43 – 0.2% of
p-ERK positive area; p > 0.05; Fig. 3C), in comparison with
control (1.30 – 0.2%; Fig. 3C). Treatment of cells over-
expressing the NO-insensitive construct with U0126 also
prevented basal phosphorylation of ERK both in NOC-18
treated cells (0.64 – 0.1% of p-ERK positive area; p < 0.05
and p < 0.01; Fig. 3C) and in control cells (0.49 – 0.1%;
Fig. 3C). Surprisingly, NOC-18 did not seem to increase the
number of cells positive for p-ERK in cells that do not appear
to be transfected with the C118S Ras construct; this could be
attributed to cells that could have been transfected with a
lower amount of Ras plasmid.
We appreciate that there is a basal p-ERK signal without
NO treatment, which is inhibited by U0126 treatment. How-
ever, it is clear that the increase observed with NOC-18 in Ras-
transfected cells is dependent on the presence of Cys118.
To show that the C118S Ras construct is insensitive to NO,
whereas p21Ras remains functional with this modification,
WT Ras- or C118S Ras-overexpressing cells were treated
with the EGFR ligand, EGF (20 ng/ml), for 20min, either
alone or with the EGFR inhibitor, AG1478 (200 nM). Al-
though there is some basal p-ERK signal, a large increase in
the phosphorylation of ERK was observed after exposure to
RAS S-NITROSYLATION PROMOTES NEUROGENESIS 17
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FIG. 1. Identification of Ras Cys118 oxidation in 2-DE gels. (A)NSCwere either not transfected (left) or transfected withWT
H-Ras (right), and protein extracts were subjected to 2-DE and stained with Sypro Ruby. The region where Ras was expected to
appear is magnified in the insets in the lower right corners. A differential spot (red circle) in the region where Ras was expected to
appear was cut, digested, and identified by LC-MS/MS as H-Ras (see Table 1). NSCs transfected withWTRas were treated with S-
nitroso-l-cysteine, protein extracts were blocked with NEM, and reversibly oxidized cysteines were reduced with DTT and labeled
with IAMbefore 2-DE. The same spot as in (A)was cut, digested, and analyzed byLC-MS/MS searching for theCys118-containing
peptide CDLAAR; MS/MS spectra for the NEM- and IAM-modified versions of the peptide [(B, C), respectively] are shown,
corresponding to reduced and oxidized states of Cys118, respectively. 2-DE, two-dimensional electrophoresis; DTT, dithiothreitol;
IAM, iodoacetamide; LC-MS/MS, liquid chromatography-tandemmass spectrometry assay;NEM,N-ethylmaleimide;NSC, neural
stem cells. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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EGF in both WT Ras (Supplementary Fig. S3B, 0.25 – 0.2%,
p < 0.001) and C118S Ras cells (Supplementary Fig. S3C,
0.77 – 0.6%, p < 0.05) in comparison with control (Supple-
mentary Fig. S3B, WT Ras: 1.01 – 0.1%; Supplementary
Fig. S3C, C118S Ras: 1.04 – 0.1%). This increase in phos-
phorylation was abolished by EGFR inhibition with AG1478
(Supplementary Fig. S3B, WT Ras: 0.75 – 0.1%, p < 0.001;
Supplementary Fig. S3C, C118S Ras: 0.83– 0.2%, p < 0.01),
thus demonstrating that C118S Ras is insensitive to NOwhile
remaining sensitive to the EGFR ligand, which is upstream of
Ras in the pathway.
SNO of Ras enhances proliferation of NSC
derived from the SVZ
Next, we evaluated the proliferation of SVZ-derived NSCs
transfected withWTRas or C118S Ras constructs. Cells were
treated with 10lM NOC-18 for 1 h, the same conditions that
were previously shown to induce proliferation, without al-
tering cell viability (6). Cell proliferation was assessed by the
incorporation of 5-ethynyl-2¢-deoxyuridine (EdU), detected
in a fluorescence microscope in cells expressing the green
fluorescent protein signal, corresponding to the over-
expression of the Ras construct.
As shown in Figure 4A–D, cell proliferation was signifi-
cantly enhanced in cells overexpressing WT Ras after treat-
ment with NOC-18 (18.96 – 0.8%, p < 0.001; Fig. 4D), when
compared with untreated WT Ras-transfected cells (10.99–
0.9%). Conversely, after exposure to NOC-18, the incorpo-
ration of EdU in C118S Ras-transfected NSCs was lower
(6.84– 0.5%; Fig. 4D), similar to the values of proliferation
in untreated C118S Ras cells (4.80 – 0.7%, p> 0.05), sug-
gesting that, in the presence of NO, SNO of Ras Cys118 was
the trigger for cell proliferation.
Further, cell proliferation was also assessed through the
fluorescent detection of the proliferation marker phospho-
histone H3 in cells transfected with WT Ras or C118S Ras
(Fig. 4E, F). Likewise, treatment with 10 lM NOC-18 sig-
nificantly increased the percentage of WT Ras-transfected
cells that expressed the phospho-histone H3 marker (1.47–
0.6%, p < 0.05; Fig. 4F), when compared with untreated
cells (0.33 – 0.04%), whereas no differences were observed
in C118S Ras-overexpressing cells (Control: 0.12 – 0.05%;
NOC-18: 0.40 – 0.2%, p> 0.05; Fig. 4F).
FIG. 2. NO increases SNO of Ras in WT Ras cells, but not in C118S Ras cells. SNO of Ras 2, 5, and 7.5min after
treatment with 10 lM NOC-18 in NSCs overexpressing WT Ras (A), and 5min after treatment with 10 lM NOC-18 in
C118S Ras cells (B) was assessed by a biotin switch assay. Data are expressed as means– SEM of at least four independent
experiments. t-Test for comparison of two population means, **p< 0.01 significantly different from control. Uncropped
images are in Supplementary Figure S7. NO, nitric oxide; SEM, standard error of the mean; SNO, S-nitrosylation.
Table 1. Peptides from H-Ras (Uniprot #Q61411) Identified from the Two-Dimensional
Electrophoresis Differential Spot Analysis in WT Ras-Transfected Neural Stem Cells
Sequence # PSMs Modifications XCorr Charge MH+ [Da] m/z [Da]
RT
[min]
SFEDIHQYR 6 2.64 2 1194.54802 597.77765 31.80
LVVVGAGGVGK 11 2.75 2 955.58556 478.29642 33.45
VKDSDDVPmVLVGNK 3 M9 (Oxidation) 4.09 2 1631.82207 816.41467 35.11
DSDDVPmVLVGNK 1 M7 (Oxidation) 2.97 2 1404.66118 702.83423 43.10
SYGIPYIETSAK 1 2.21 2 1328.66594 664.83661 48.78
QGVEDAFYTLVR 1 3.53 2 1397.70134 699.35431 59.05
TGEGFLcVFAINNTK 1 C7 (Carbamidomethyl) 4.29 2 1670.81597 835.91162 60.38
MH+, protonated monoisotopic mass; m/z, mass-to-charge ratio; # PSMs, number of peptide to spectrum matches; RT, retention time;
XCorr, raw cross-correlation score of the top PSM.
RAS S-NITROSYLATION PROMOTES NEUROGENESIS 19
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FIG. 3. NO increases phos-
phorylation of ERK1/2 in WT
Ras cells, but not in C118S Ras
cells. NSCs were transfected with
WT Ras or C118S Ras and treated
for 20min with 10 lM NOC-18,
1 lM U0126 (MEK1/2 inhibitor),
or both. Then, the levels of
phospho-ERK and Ras were ana-
lyzed by immunofluorescence
microscopy as described in the
section ‘‘Materials and Methods.’’
(A) Representative images show-
ing phospho-ERK in gray (supe-
rior panels) and green (inferior
panels), Ras in red, and nuclei
in blue. Scale bar: 50lm. (B, C)
Quantification of % of p-ERK
positive area in transfected, Ras-
overexpressing NSCs; WT Ras
(B); C118S Ras (C). (D, E)
Quantification of % of p-ERK
positive area in transfected, Ras-
negative NSCs; WT Ras (D);
C118S Ras (E). Data represent
mean – SEM of a minimum of
five independent experiments. One-
way ANOVA (Bonferroni’s post-
test), *p < 0.05 and **p < 0.01
significantly different from con-
trol, and +p < 0.05, ++p < 0.01 and
+++p < 0.001 significantly different
from NOC-18-treated cells. ANO-
VA, analysis of variance; ERK,
extracellular signal-regulated ki-
nase; MEK, mitogen-activated
protein kinase kinase; p-ERK,
phospho-ERK. To see this illus-
tration in color, the reader is re-
ferred to the web version of this
article at www.liebertpub.com/ars
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FIG. 4. NO stimulates proliferation of WT Ras-overexpressing SVZ-derived neural stem cells. Evaluation of cell
proliferation was assessed by EdU incorporation (A–D) and phospho-histone H3 immunofluorescence (E, F). (A–D) NSCs
co-transfected with WT Ras construct or C118S Ras construct and GFP were treated with 10 lM NOC-18 and 10lM EdU
for 1 h. (A) Representative images are shown. Cells that incorporated EdU are shown in magenta, and transfected cells are
shown in green. Nuclei were labeled with Hoechst 33342 (blue). White arrows show transfected cells that incorporated
EdU. Scale bar: 20lm. (B) Example of an EdU-labeled transfected cell, showing co-localization of Hoechst (blue), Ras-
GFP (green), and EdU (magenta). (C) Example of an EdU-labeled non-transfected cell, showing co-localization of Hoechst
(blue) and EdU (magenta), but not with Ras-GFP (green). (D) Analysis of the percentage of transfected cells that incor-
porated EdU, in comparison with the total of GFP-positive cells, compared with the total of live cells. Data are expressed as
means – SEM of three independent experiments. Two-way ANOVA (Bonferroni’s post-test), ***p < 0.001, significantly
different from control. (E, F) NSCs transfected with WT Ras or C118S Ras constructs were treated with 10 lM NOC-18 for
1 h. Cell proliferation was assessed by immunofluorescence microscopy analysis of the proliferation marker phospho-
histone H3. (E) Representative images showing phospho-histone H3-positive cells in magenta, and transfected cells in
green. Nuclei were labeled with Hoechst 33342 (blue). White arrows show transfected cells that are positive for phospho-
histone H3. Scale bar: 20 lm. (F) Percentage of transfected cells positive for phospho-histone H3, relative to the total of
transfected cells. Data are expressed as means –SEM of five independent experiments. Two-way ANOVA (Bonferroni’s
post-test), *p < 0.05, significantly different from control. EdU, 5-ethynyl-2¢-deoxyuridine; GFP, green fluorescent protein;
SVZ, subventricular zone. To see this illustration in color, the reader is referred to the web version of this article at www
.liebertpub.com/ars
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NOC-18 did not enhance the formation
of 3-nitrotyrosine
To rule out the possible tyrosine nitration mediated by the
possible formation of peroxynitrite from NOC-18, which
could negatively affect the neurogenic potential of NO so far
described, we assessed the formation of 3-nitrotyrosine (3-
NT) by Western blot. Our results demonstrated that in NSCs
derived from the SVZ, either non-transfected or transfected
withWTRas or C118S Ras, there was no production of 3-NT,
as compared with the positive controls used in this study,
1mM peroxynitrite and nitrated bovine serum albumin
(BSA) (Supplementary Fig. S4A). Moreover, similar results
were observed in in vivo samples of the dentate gyrus of
saline-treated or kainic acid (KA)-treated inducible nitric
oxide synthase (iNOS)+/+ and iNOS-/- animals, in which no
expression of 3-NT was detected in these samples, nor an
increase was observed in animals treated with KA, when
compared with positive controls (Supplementary Fig. S4B).
Further characterization of the expression of the different
nitric oxide synthase (NOS) isoforms showed that none of the
NOS isoforms was detected by Western blot in SVZ-derived
NSCs that were either non-transfected or transfected with
WT Ras or C118S Ras (Supplementary Fig. S5A), whereas
neuronal and endothelial NOS were detected in in vivo
samples of the dentate gyrus of saline-treated iNOS+/+ or
iNOS-/- mice (Supplementary Fig. S5B).
iNOS-derived NO induces SNO of p21Ras
after seizures
We previously characterized the production of iNOS-
derived NO after seizures, which increases neurogenesis in
the dentate gyrus; NO stimulates the proliferation of NSC in
the dentate gyrus, starting at 2 days after the onset of seizures
and peaking at 5 days, an effect that is completely lost in
iNOS knockout mice (6). To study whether p21Ras is mod-
ified by NO released after brain injury, seizures were induced
in WTmice or in mice lacking iNOS by the administration of
25mg/kg of KA. Animals were sacrificed and the dentate
gyrus was dissected 1, 2, 3, or 5 days after treatment with KA
or saline solution (control comparison group). Oxidation of
Ras was detected by the redox biotin switch (17). This
technique allows the detection of several reversible oxidative
cysteine modifications, including SNO, with high sensitivity
in tissue samples, in which sensitivity can be an issue.
Our results showed a significant increase in the reversible
cysteine oxidation of Ras in WT mice 2 days after seizures
(2 days: 103.73 – 7.1, p < 0.001, Fig. 5A), and a decrease
3 days after seizures (3 days: 26.49– 4.4, p < 0.05, Fig. 5A),
but no significant differences were observed 1 and 5 days
after seizures (1 day: 57.56– 5.2, p> 0.05; 5 days: 27.15 –
6.8, p > 0.05, Fig. 5A), in comparison with saline-treated
mice (1 day: 34.92– 5.1; 2 days: 57.17– 8.1; 3 days: 56.02–
13.4; 5 days: 33.26 – 7.1). However, in mice lacking iNOS,
no significant differences in Ras oxidation were observed
after seizures in any of the times studied here (1 day:
53.10 – 12.5; 2 days: 57.08 – 23.4; 3 days: 32.99– 3.8; 5 days:
80.67 – 30.9, p > 0.05; Fig. 5B), when compared with saline-
treated mice (1 day: 40.01– 10.7; 2 days: 52.97 – 11.0;
3 days: 53.99 – 13.8; 5 days: 48.57 – 20.5).
In addition, to confirm that the differences observed in Ras
oxidation in WT mice after seizures corresponded to differ-
ences in SNO, we performed a classical biotin switch assay
(with ascorbate as reducing agent; it is specific for SNO, but
provides less sensitivity than the redox biotin switch) in
samples of the dentate gyrus obtained from seizured WT
mice and respective saline-treated controls. Consistently, we
observed an increase in Ras SNO 2 days after seizures
(2 days: 70.24– 3.9, p < 0.01; Fig. 5C), but not 1, 3, and
5 days after seizures (1 day: 46.51 – 4.7, p> 0.05; 3 days:
48.42 – 5.8, p > 0.05; 5 days: 42.38 – 6.1, p> 0.05; Fig. 5C), in
comparison with saline-treated mice (1 day: 37.02– 2.9;
2 days: 49.13 – 3.9; 3 days: 50.37 – 7.1; 5 days: 58.43 – 6.1).
These findings show that NO produced by iNOS after sei-
zures modifies Ras by SNO, thus suggesting Ras as an im-
portant mediator for the neurogenic upregulation observed in
the hippocampus after seizures.
Discussion
Redox modulation of proteins is crucial in several cell
signaling events involving reactive species, particularly NO.
Similar to other post-translational modifications, cysteine
SNO in critical residues may modulate protein function.
Previous studies identified the Cys118 of Ras as a target of
SNO by NO, which increased Ras activity (20). In the data
presented here, we identified Ras, on its Cys118, as a direct
target of the neurogenic effect of NO in NSCs.
Our findings show that Ras is rapidly modified by SNO in
the Cys118 when NSCs are treated with a low amount of NO,
since no increase in SNO was observed when cells over-
expressing the NO-insensitive C118S Ras were exposed to
NO. We have also found an increase in the proliferation of
NSCs in cells overexpressing WT Ras, but not in C118S Ras
cells. Our current results are in agreement with our previous
work, in which we showed that the EGFR was not the first
target of NO in the ERK/MAPK pathway (6).
Further, contrary to the report of the other group in which
the authors showed that the EGFR is S-nitrosylated and,
consequently, loses its tyrosine kinase activity, here we show
that EGFR activity seems to be maintained as treatment with
EGF activates the downstream ERK/MAPK pathway (34). In
addition,Moraes et al. recently showed that SNOof the EGFR
stimulates the receptor activity and, subsequently, enhances
cell proliferation and angiogenesis in endothelial cells after
exposure to bradykinin (30). In that work, they also showed
that NO-mediated activation of the ERK/MAPK pathway
leads to ERK1/2-mediated phosphorylation of specific Thr
residues of the EGFR, preventing EGFR internalization and
resulting in sustained signaling (30); thus, there can be up-
stream effects that are mediated by downstream components
of the EGF-Ras-ERK pathway. Moreover, we observed the
activation of the downstream elements of Ras, including c-
Raf1 and ERK1/2, suggesting that p21Ras could be the first
protein to be activated by NO (6).
In addition, we show that the phosphorylation of ERK
induced by NO depends on the Cys118 of Ras, highlighting
the role of the NO modification of this cysteine residue.
However, in cells that overexpress the NO-insensitive Ras,
the phosphorylation of ERK by other mechanisms, such as
the activation of the EGFR with EGF, is preserved. Thus,
there is no loss of function of Ras in the ERK pathway and the
lack of effect of NO in Ras C118S cells is caused by the
inability to modify Cys118 and not by a non-functional Ras.
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Taken together, our findings point out Ras as one of the first
targets of NO in the ERK/MAPK pathway in the NO-induced
proliferation of NSCs in the SVZ, as suggested in Figure 6.
Although classical effects of NO, such as its vasodilating
properties, occur through an interaction with soluble guany-
lyl cyclase, other signaling events are independent of cGMP
and based on post-translational modifications (26). For in-
stance, in endothelial cells, SNO of Ras at Cys118 is the
trigger for the stimulation of cell proliferation via activation
of the ERK/MAPK pathway (3). Also, activation of the ERK/
MAPK pathway was described in T cells, being important for
its activation and development (16). Moreover, our findings
do not exclude the activation of other pathways by NO
through cGMP-dependent or -independent mechanisms, and
the interaction between effectors of different pathways. In
fact, we previously reported the activation of the sGC/cGMP/
PKG pathway by NO, in addition to the ERK/MAPK path-
way, in the stimulation of NSC proliferation (7). In that work,
we showed that the activation of both pathways by NO is
biphasic: an initial activation of the ERK/MAPK pathway
and, in longer periods, activation of the sGC/cGMP/PKG
pathway (7). Moreover, the involvement of the PI3K/Akt
pathway in the proliferative effect of NO in human endo-
thelial cells is also suggested by other studies (3).
SNO of several proteins involved in neurogenesis has been
reported [reviewed in ref. (44)]. In some proteins, such as
p21Ras, SNO stimulates neurogenesis; whereas in other
proteins, SNO is described as anti-neurogenic. For example,
MEF2 is a positive regulator of neurogenesis in physiologi-
cal conditions, but, in the presence of increased levels of
NO, as in some neurodegenerative conditions, MEF2 is S-
nitrosylated at Cys39, resulting in an inhibition of neuro-
genesis and stimulating neurodegeneration (36). Also, SNO
of the EGFR in two Cys residues was suggested to be in-
volved in the antiproliferative role of NO in the SVZ (34).
Hence, the evidence that SNO of Ras is able to positively
regulate neurogenesis makes Ras a possible therapeutic target
for conditions in which neurogenesis is impaired. Further,
Ras is an upstream protein of the ERK/MAPK pathway, one
of the main signaling pathways in the cell, whose activation
FIG. 5. Reversible cysteine oxidation (Oxid.) and SNO of Ras is increased 2 days after seizures in iNOS1/1 mice,
but not in iNOS2/2 mice. Oxidation of Ras 1, 2, 3, and 5 days after KA or SAL treatment in iNOS+/+ mice (A) and in
iNOS-/- mice (B) was assessed by a DTT-reducing biotin switch assay, and SNO of Ras (C) was assessed by an ascorbate-
reducing biotin switch assay. Data are expressed as means– SEM of the ratio of Oxid. or SNO Ras signal with the total Ras
for at least four independent experiments. Two-way ANOVA (Bonferroni’s post-test), *p< 0.05 and ***p < 0.001 signifi-
cantly different from the respective saline treatment. Uncropped images are in Supplementary Figure S7. iNOS, inducible
nitric oxide synthase; KA, kainic acid; SAL, saline solution.
RAS S-NITROSYLATION PROMOTES NEUROGENESIS 23
D
ow
nl
oa
de
d 
by
 C
en
tro
 D
e 
Bi
ol
og
ia
 M
ol
ec
ul
ar
 S
ev
er
o 
O
ch
oa
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 1
2/
12
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
results in the activation of several transcription factors, in-
cluding cAMP response element-binding protein, c-Fos,
Elk-1, and c-Myc (6). Hence, through the activation of this
pathway, cells can achieve signal amplification and a more
pronounced effect on proliferation.
One of the hallmarks of several acute and chronic neuro-
degenerative diseases is the overproduction of NO in the
brain, which favors protein SNO (35). NO of an inflammatory
origin in the brain is derived from iNOS, which is mainly
expressed in activated microglial cells. In this study, we used
a well-described seizure model of acute excitotoxic brain
injury (45), characterized by neuronal loss in the hippocam-
pus accompanied by activation of microglia and neuroin-
flammation, which presents an increase in the proliferation of
NSCs (starting 2 days after seizures) and neurogenesis in the
dentate gyrus of WT mice after seizures (6). We observed
increased levels of oxidized Ras, specifically S-nitrosylated
Ras, in the dentate gyrus of WT mice 2 days after seizures.
These data point to a temporal overlap between Ras SNO
(2 days after seizures) and cell proliferation (also increases
significantly at 2 days after seizures and peaks at 5 days) in
this seizure model, as shown in Supplementary Figure S6. In
fact, the peak of Ras SNO observed 2 days after seizures
precedes the peak in cell proliferation (5 days) previously
observed after seizures in mice (6). A similar pattern was
observed in SVZ cultures, on a different time scale: The in-
crease in cell proliferation observed at 60min after exposure
to NO in NSCs follows the peak of Ras SNO at 5min
(Supplementary Fig. S6).
Moreover, in iNOS-/- mice, in which NSC proliferation
and neurogenesis after seizures are impaired (6), modifica-
tion of Ras was not observed, suggesting that iNOS-derived
NO is responsible for Ras oxidation/SNO. Although in this
study we have focused on the effect on cell proliferation, our
FIG. 6. Proposed model for the activation of the ERK/MAPK pathway by NO through Ras SNO. NO bypasses the
EGFR because it S-nitrosylates Ras on Cys118, thus activating it. The elements downstream Ras, including Raf, MEK1/2,
and ERK1/2, are activated, mainly by phosphorylation. ERK can activate other factors such as p90RSK and, when
phosphorylated, ERK and p90RSK are translocated to the nucleus, where they trigger transcription of genes involved in
biological processes, such as cell proliferation. Activated p90RSK also inhibits p27KIP1, which is translocated to the
cytoplasm and then degraded in the proteasome, thus allowing for cell cycle progression. Ras can still be activated by the
EGFR, independently of its Cys118. CREB, cAMP response element-binding protein; GAP, GTPase activating protein;
GEF, guanine nucleotide exchange factor; GRB-2, growth factor receptor-bound protein 2; EGF, epidermal growth factor;
EGFR, EGF receptor; ERK1/2, extracellular signal-regulated kinase 1 and 2; MEK1/2, mitogen-activated protein kinase
kinase 1 and 2; p27KIP1, cyclin-dependent kinase inhibitor 1; p90RSK, p90 ribosomal S6 kinase; SOS, son of sevenless. To
see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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previous study show that NO produced in this injury context
was shown to be essential for the proliferation of the early-
born NSC, migration of neuroblasts, and distribution of
newborn cells in the dentate gyrus after seizures (8).We show
here that Ras SNO is an early critical event in the timeline of
the stimulation of hippocampal neurogenesis by NO.
Altogether, our findings help in better understanding the
role of SNO of Ras in cell proliferation both in vitro and
in vivo, in the context of an acute excitotoxic lesion that
affects neurogenesis in the hippocampus. We identified
Ras SNO as one of the first targets of NO in NSC, and as a
possible therapeutic target for NO-based therapeutic ap-
proaches aiming at the stimulation of neurogenesis for re-
pairing brain injury.
Materials and Methods
Reagents and chemicals
Dulbecco’s modified Eagle’s medium (D-MEM)/F-12
with 2mM GlutaMAX TM-I, B27, Penicillin-Streptomycin
(10,000U/ml), Lipofectamine LTX, Optimem Reduced
Serum Medium, Click-iT EdU Alexa Fluor 594 HCS
Assay kit, immunoglobulin Gs (IgGs) conjugated with Alexa
Fluor 488, 594, or 633, and Hoechst 33342 were purchased
from Life Technologies (Carlsbad, CA). Amaxa Mouse
NSC Nucleofector Kit was from Lonza (Basel, Switzer-
land). EGF and basic fibroblast growth factor (bFGF) were
from Peprotech (London, United Kingdom). KA was ob-
tained from Ocean Produce (Charlottetown, Canada). NOC-
18 was purchased from Alexis Biochemicals (San Diego,
CA), and AG1478 was from Tocris Bioscience (Bristol,
United Kingdom). U0126 and horseradish peroxidase (HRP)
secondary anti-mouse antibody conjugate were purchased
from Cell Signaling (Danvers, MA). Mouse anti-Ras antibody
and nitrated BSA were fromMillipore (Darmstadt, Germany).
N-[6-(Biotinamido)hexyl]-3¢-(2¢-pyridyldithio)propionamide
(Biotin-HPDP) and Ultralink immobilized neutravidin resin
were obtained from Thermo Fisher Scientific (Waltham,
MA), and streptavidin-peroxidase was fromCalbiochem (San
Diego, CA). NEM, sodium ascorbate, DTT, IAM,mouse anti-
a-tubulin antibody, and poly-l-lysine were purchased from
Sigma Chemical (St. Louis, MO). Peroxynitrite was from
Cayman Chemical (Ann Harbor, MI). Polyvinylidene difluoride
(PVDF) membranes and Clarity Western ECL substrate were
purchased from Bio-Rad Laboratories (Hercules, CA). The or-
igin of the primary antibodies is mentioned in the text.
Animals
C57BL/6J newborn mice and 12-week-old C57BL/6J
(iNOS+/+) male mice were obtained from Charles River
(Barcelona, Spain). Twelve-week-old B6.129P2-Nos2tm1Lau/
J (iNOS-/-) male mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). All the animals were kept in
our animal facilities with food and water ad libitum in a 12 h
dark:light cycle. The weight of the animals varied between 20
and 30 g. All experiments were performed in accordance with
NIH and European guidelines (2010/63/EU) for the care and
use of laboratory animals. The animals were housed in the
Centre for Neuroscience and Cell Biology, Coimbra, Portu-
gal, a licensed animal facility (International Animal Welfare
Assurance number 520.000.000.2006).
SVZ NSC cultures
NSC cultures were obtained from the SVZ of 0–3 day
C57BL/6J mice and maintained as previously described (1,
6). NSCs grown as floating neurospheres in D-MEM:F-12
nutrient mixture (D-MEM/F-12 with 2mM GlutaMAXTM-I
[l-Ala-l-Gln]), supplemented with 1% B27, 1% antibiotic
(10,000U/ml of penicillin, 10mg/ml streptomycin), 10 ng/ml
EGF, and 5 ng/ml bFGF, were collected and plated for 2–
3 days onto poly-l-lysine-coated plates. Then, growth factors
were excluded from the medium and cells were kept in this
medium for 24 h before the experiments.
Plasmids and transfection
WT Ras (H-Ras isoform, human sequence, identical to the
mouse amino acid sequence) and C118S Ras constructs were
a kind gift by Dr. Kenneth K. Teng (20). In the C118S Ras
plasmid, the cysteine 118 was replaced by a residue of serine,
an NO-insensitive form of p21Ras that cannot be S-
nitrosylated. For analysis of EdU incorporation, NSCs were
transfected with the Amaxa Mouse NSC Nucleofector Kit
(Lonza) and for the other experiments, Lipofectamine LTX
(Life Technologies) was used.
For nucleofection, neurospheres with 3–5 passages were
harvested, pelleted, and dissociated and the cells were
counted. Overall, 2–4· 106 cells were used per nucleofection
sample. Cells were pelleted, and the supernatant was com-
pletely removed. Five micrograms of DNA (WT Ras or
C118S Ras) plus 2 lg of pmaxGFP vector were added to
100ll of Mouse NSC Nucleofector Solution. The cell pellet
was resuspended in the solution with the DNA and trans-
ferred to the cuvette. The program A-033 of the Nucleofector
II Device (Lonza, Basel, Switzerland) was used. The suspension
containing the transfected cells was plated onto poly-l-lysine-
coated 16-mm-diameter glass coverslips, and pre-warmed SVZ
mediumwas added. A control of transfectionwas performed by
exposure of NSCs to the same conditions, except the constructs
(Mock). Cells were incubated for 2–3 days in a humidified
37C/5% CO2 incubator. Culture medium was replaced 24 h
after nucleofection by a similar SVZ fresh medium. Gene
expression could be detected 48 h after nucleofection.
For Lipofectamine transfection, neurospheres were disso-
ciated and plated onto poly-l-lysine-coated 16-mm-diameter
glass coverslips or 12-well plates. Cells grew for*2 days in
a humidified 37C/5% CO2 incubator and were transfected
with 50–70% confluence by using Lipofectamine LTX and
Plus Reagent. For transfection, 1 lg of DNA (WT Ras or
C118S Ras) and 2.5 ll of Plus Reagent were added to 100 ll
of Optimem Reduced Serum Medium and incubated for
10min. Then, 1.5ll of Lipofectamine LTX was added to the
mixture, mixed, and incubated for 30min at room temperature
(RT). Complexes were then added, drop by drop, to the cells
containing SVZ medium without antibiotics. Gene expression
could be detected 8–48 h after transfection. Culture medium
was replaced 24 h after transfection by SVZ medium without
growth factors, and experiments were performed 24 h later.
2-DE and MS
For the identification of S-nitrosylated Ras, NSCs were
treated with 100lM CysSNO for 15min, prepared as pre-
viously described (19). Cells were lysed; proteins were
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separated by 2-DE using 7-cm pI 4–7 immobilized pHgradient
strips and 10% sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis (PAGE), and they were stained with
Sypro Ruby, as previously described (17, 49). Spots were
picked, digested, and analyzed by LC-MS/MS in the Pro-
teomics Unit of the Centro de Biologı´a Molecular Severo
Ochoa (CBMSO) as detailed below.
In-gel digestion
After drying, gel spots were destained in acetonitrile:water
(ACN:H2O, 1:1) and digested in situ with sequencing-grade
trypsin (Promega, Madison, WI) as described by Shevchenko
et al. (46) with minor modifications (40). The gel pieces were
shrunk by removing all liquid by using sufficient ACN. ACN
was pipetted out, and the gel pieces were dried in a speedvac.
The dried gel pieces were re-swollen in 50mM ammonium
bicarbonate pH 8.8 with 12.5 ng/ll trypsin for 1 h in an ice
bath. The digestion buffer was removed, and gels were
covered again with 50mM ammonium bicarbonate pH 8.8
and incubated at 37C for 12 h. Digestion was stopped by the
addition of 1% trifluoroacetic acid. Whole supernatants were
dried down and then desalted onto ZipTip C18 Pipette tips
(Millipore) until the mass spectrometric analysis.
Reverse-phase LC-MS/MS assay in SMIM mode
The desalted protein digest was dried, resuspended in 10 ll
of 0.1% formic acid, and analyzed by reverse-phase LC-
MS/MS in an Easy-nLC II system coupled to an ion trap
LTQ-Orbitrap-Velos-Pro mass spectrometer (Thermo Fisher
Scientific). The peptides were concentrated (on-line) by
reverse-phase chromatography by using a 0.1mm · 20mm
precolumn Acclaim PepMap C18, 5 lm, 100 A˚ (Thermo
Fisher Scientific), and they were then separated by using a
0.075mm · 25 cm column Acclaim PepMap C18, 3 lm, 100
A˚ (Thermo Fisher Scientific) operating at 0.3 ll/min. Pep-
tides were eluted by using a 60-min gradient from 5% to 40%
solvent B (Solvent A: 0.1% formic acid in water; solvent B:
0.1% formic acid, 80% ACN in water). Electrospay ioniza-
tion was done by using a Nano-bore emitters Stainless Steel
ID 30 lm (Proxeon) interface (31).
The Orbitrap resolution was set at 30,000. Peptides were
detected in survey scans from 400 to 1600 amu (1 lscan),
followed by selected MS/MS ion monitoring (SMIM) events
when necessary (the number of events depends on the pep-
tides to be monitored) plus 10 data-dependent MS/MS scans,
using an isolation width of 2U (in mass-to-charge ratio
units), normalized collision energy of 35%, and dynamic
exclusion applied during 30 s periods.
To find peptides in a directed way, the mass spectrometer
was operated in the selected MS/MS ion monitoring mode
(SMIM mode) (18). In this mode, the LTQ-Orbitrap-Velos-
Pro detector was programmed to perform, along the same
entire gradient, a continuous sequential operation in the
MS/MS mode on the doubly or triply charged ions corre-
sponding to the peptide/s previously selected from the theo-
retical prediction.
Peptide identification from raw data was carried out by
using the SEQUEST algorithm (Proteome Discoverer 1.4;
Thermo Fisher Scientific). A database search was performed
against the handmade database. The following constraints
were used for the searches: tryptic cleavage after Arg and
Lys, up to two missed cleavage sites, and tolerances of 20
ppm for precursor ions and 0.8 Da for MS/MS fragment
ions and the searches were performed, allowing optional
Met oxidation, Cys carbamidomethylation, and Cys NEM
modification. Search against the decoy database (integrated
decoy approach) was carried out by using a false discovery
rate <0.01.
To confirm the identification of peptides monitored,
the MS/MS spectra were manually analyzed by assigning the
fragments to the candidate sequence, after calculation of
the series of theoretical fragmentations, according to the
nomenclature of the series as previously described (42).
Cell lysates for biotin switch assay
For the assessment of Ras SNO, NSCs overexpressing
WT Ras or C118S Ras were treated for 2, 5, or 7.5min with
10 lM NOC-18, the concentration previously used to stim-
ulate proliferation of NSCs from the SVZ (6). After treat-
ment, cells were washed with cold 0.9% NaCl, and they
were then scraped and lysed in TENT pH 6.0 (50mM Tris-
HCl, 1mM ethylenediaminetetraacetic acid [EDTA], 0.1mM
neocuproine, 1% Triton X-100, pH 6.0) supplemented with
50mM NEM to block the free thiols, and protease inhibitors
(freshly added), protected from light. Four 2-s sonication
cycles were applied. To complete the blocking reaction, 2%
SDS was added to the lysate and incubated for 30min at
37C. Protein concentration was determined by the bicinch-
oninic acid assay method.
Administration of KA
Adult male wild-type C57BL/6J and iNOS-deficient mice
of 12 weeks of age were treated with KA solution that was
injected subcutaneously (25mg/kg) and the respective con-
trols were treated with a sterile saline solution (0.9% NaCl in
water, pH 7.4), as previously described (6). All animals that
received KA developed grade five seizures or higher in the
1972’s Racine’s six-point scale modified for mice (45). In
animals injected with saline solution alone, no seizures were
observed and they were used as controls. The mice were
maintained for 1–5 days after the first generalized seizure. At
least three animals survived in each experimental group.
Dissection of the dentate gyrus and lysates
The dentate gyrus of each animal was dissected in Hanks’
Balanced Salt Solution and mechanically lysed with a tis-
sue homogenizer in TENT pH 6.0 (50mM Tris-HCl, 1mM
EDTA, 0.1mM Neocuproine, 0.5% Triton X-100, pH 6.0)
supplemented with 50mM NEM to block the free thiols, and
protease inhibitors. Four 2-s sonication cycles were applied.
Two percent SDS was added to the lysate, and it was incu-
bated for 30min at 37C to complete the blocking reaction.
Protein concentration was determined by the bicinchoninic
acid assay method.
Biotin switch assay
Determination of SNO by the biotin switch assay and of
reversible Cys oxidation by the redox biotin switch assay was
performed as described in Izquierdo-Alvarez et al. and
Martinez-Ruiz and Lamas (17, 28), both in in vivo samples
and in in vitro treated cell extracts after thiol blocking.
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For the assessment of Ras SNO in transfected NSC, 200lg
of protein was used, and for in vivo assessment of Ras oxi-
dation and SNO, 500 and 1000lg of protein were used, re-
spectively. Lysates were precipitated with acetone, and
the pellet was resuspended in TENS pH 7.2 (50mM Tris-
HCl, 1mM EDTA, 0.1mM neocuproine, 1% SDS, pH 7.2);
2.5mM DTT or 100mM sodium ascorbate was added to
reduce oxidized thiols or specifically nitrosothiols, respec-
tively. The reduced thiols were labeled with 1mM biotin-
HPDP for 1 h. Until this point, all operations were carried out
in the dark. Samples were precipitated with acetone and re-
suspended in HENS (250mM Hepes pH 7.7, 1mM EDTA,
0.1mM neocuproine, 1% SDS); then, a neutralization buffer
(20mM Hepes pH 7.7, 1mM EDTA, 100mM NaCl, 0.5%
Triton) was added, followed by centrifugation at 13,400 rpm
for 1min. One hundred microliter of the supernatant was
saved as the Input fraction (total Ras), and the rest was added
to the pre-equilibrated Ultralink immobilized neutravidin
resin. Samples were incubated with the resin for 1 h at RT
with agitation. After washing, 100ll of elution buffer was
added (20mM Hepes pH 7.7, 100mM NaCl, 1mM EDTA
+100mM 2-mercaptoethanol) and incubated for 20min at
37C for elution of the proteins that bound to the resin. Then,
the mixture was centrifuged for 1min, at 14,500 rpm and
the supernatant was saved as the eluted fraction (oxidized/
SNO proteins).
For Ras analysis by Western blot, the eluted fraction and
respective input samples were denatured at 95C for 5min
with a reducing Laemlli buffer and then subjected to an
electrophoresis in 12% SDS/PAGE gels, transferred to PVDF
membranes, blocked with 5% low-fat dry milk, and finally
incubated with the primary antibody (mouse anti-Ras,
1:2000; Millipore) overnight, at 4C. After incubation with
the HRP secondary anti-mouse antibody conjugate (1:2000),
membranes were incubated with the Clarity Western ECL
Substrate (Bio-Rad Laboratories), and immunoreactive bands
were visualized in the Molecular Imager ChemiDocTM
XRS+ Imaging System (Bio-Rad Laboratories). Image bands
were analyzed with the ImageLab software version 5.1 (Bio-
Rad Laboratories).
Analysis of cell proliferation by EdU incorporation
SVZ-derived NSCs were treated for 1 h with 10lM NOC-
18, and proliferation was assessed by incorporation of EdU
by using the Click-iT EdUAlexa Fluor 594 HCSAssay kit
(Life Technologies) as previously described (33, 43). Ten
micromolar EdU was added to the SVZ cultures at the time
of the treatment (1 h). Nuclei were stained with Hoechst
33342 (2 lg/ml) for 5min. Images were acquired in an epi-
fluorescence microscope (Axioskop 2 Plus; Zeiss, Jena,
Germany). Cells were counted in 8–9 different images per
condition, corresponding to a minimum of 1000 live cells per
condition. Results of labeled cells are expressed as percent-
age of total live cells. Representative images were acquired in
a laser confocal microscope Zeiss LSM 710 (Zeiss).
Analysis of ERK phosphorylation
NSCs transfected with WT Ras and C118S Ras constructs
were treated for 20min with 10 lM NOC-18 or 20 nM EGF
and for 30min with the MEK1/2 inhibitor, 1lM U0126, or
with the EGFR inhibitor, 1 lM AG1478. After treatment,
cells were fixed with 4% paraformaldehyde/4% sucrose in
phosphate-buffered saline (PBS), for 20min. Fixed cells
were permeabilized with 1% Triton X-100 in PBS for 5min,
and the non-specific binding was blocked with albumin so-
lution (3% BSA and 0.2% Tween-20 in PBS) for 1 h. For
evaluation of ERK phosphorylation, the incubation with
primary antibodies (rabbit anti-phospho-ERK1/2, 1:1000
[Cell Signaling], and mouse anti-Ras, 1:1000 [Millipore] in
3% albumin solution) was performed overnight, at 4C. After
rinsing with PBS, the cells were exposed to the appropriate
secondary antibodies, anti-mouse or anti-rabbit IgGs conju-
gated with Alexa Fluor 594 or 488, respectively, 1:200, in 3%
albumin solution, for 90min, at RT. Nuclei were stained with
Hoechst 33342 (2 lg/ml) for 5min. Controls with mock
transfection and without primary antibody were also per-
formed (not shown).
Images were acquired in a laser confocal microscope Zeiss
LSM 710 (Zeiss). Results of labeled cells are expressed as
percentage of the phospho-ERK fluorescent area of the
transfected cells of seven independent experiments. Ten im-
ages per condition were analyzed by using Image J software
(version 1.44; NIH, Bethesda). In each image, the entire area
corresponding to transfected cells was selected and the per-
centage of p-ERK positive area was calculated by the p-ERK
positive area in the transfected cells in function of the total
area of the image (45,177 lm2), as previously described (6).
Analysis of cell proliferation by immunofluorescence
NSCs transfected with WT Ras and C118S Ras constructs
were treated for 1 h with 10 lM NOC-18. Cells were fixed,
permeabilized, and blocked as detailed earlier. The primary
antibodies rabbit anti-phospho-histone H3 and mouse anti-
Ras, 1:1000 (Millipore), were incubated for 90min, at RT.
After rinsing with PBS, the cells were exposed to the ap-
propriate secondary antibodies, anti-mouse or anti-rabbit
IgGs conjugated with Alexa Fluor 488 or 594, respectively,
1:200, in 3% albumin solution, for 90min, at RT. Nuclei were
stained with Hoechst 33342 (2 lg/ml) for 5min.
Images were acquired in an epifluorescence microscope
(Axioskop 2 Plus; Zeiss). Cells were counted in 8–9 different
images per condition, corresponding to a minimum of 1000
live cells per condition. Results of labeled cells are expressed
as percentage of total live cells.
Characterization of WT Ras-transfected SVZ cultures
NSCs transfected with WT Ras construct were fixed,
permeabilized, and blocked as detailed earlier. The primary
antibodies mouse anti-nestin, 1:30, goat anti-Sox 2, 1:30,
goat anti-Sox 2, 1:200 (R&D Systems), rat anti-GFAP, 1:500
(Novex), mouse anti-Tuj1, 1:500 (Covance), rabbit anti-Ras,
1:200 (Abcam), and mouse anti-Ras, 1:1000 (Millipore),
were incubated for 90min, at RT. After rinsing with PBS, the
cells were exposed to the appropriate secondary antibodies,
anti-mouse, anti-rabbit, anti-goat, or anti-rat IgGs conjugated
with Alexa Fluor 488, 594, or 633, 1:200, in 3% albumin
solution, for 90min, at RT. Nuclei were stained with Hoechst
33342 (2lg/ml) for 5min.
Images were acquired in a laser confocal microscope Zeiss
LSM 710 (Zeiss), and around 10 images per condition, corre-
sponding to*1000 live cells, were manually counted. Results
RAS S-NITROSYLATION PROMOTES NEUROGENESIS 27
D
ow
nl
oa
de
d 
by
 C
en
tro
 D
e 
Bi
ol
og
ia
 M
ol
ec
ul
ar
 S
ev
er
o 
O
ch
oa
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 1
2/
12
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
of labeled cells are expressed as percentage of live cells trans-
fected with WT Ras of three independent experiments.
Western blotting for detection of Ras overexpression,
NOS isoforms, and 3-NT
Treated cells were washed with PBS 0.01 M, scraped, and
lysed in 50mM Tris-HCl pH 7.5, 2mM MgCl2, 10mM ethy-
lene glycol-bis(2-aminoethylether)-N,N,N¢,N¢-tetraacetic acid,
and 1% Triton X-100, supplemented with protease inhibitors
(cOmplete mini; Roche), phosphatase inhibitors (PhosSTOP;
Roche), and 1lM DTT, at 4C. Three freezing/thawing cycles
followed by five 5-s sonication cycles were applied, and total
extracts were obtained. Protein concentration was determined
by the bicinchoninic acid assay method. Then, 6· concentrated
sample buffer was added and samples were denatured at 95C
for 5min. Samples were analyzed by Western blot.
Samples were electrophoresed in SDS-PAGE by using
MiniPROTEAN 3 systems (Bio-Rad Laboratories). Gels
were composed by 6% (for NOS) or 12% (for Ras and 3-NT)
SDS-PAGE gels. Equal amounts of protein were applied
on each lane of the SDS-PAGE gels submerged in a run-
ning buffer. Proteins were separated by electrophoresis, until
proper band separation was reached. A molecular ladder
was used to control separation according to molecular
mass. Proteins were electrophoretically transferred to PVDF
membranes by using the Trans-Blot Turbo apparatus (Bio-
Rad Laboratories).
Membranes were blocked by a 1 h incubation at RT with
Tris-buffered saline containing 0.1% Tween-20 (TBS-T) and
3% BSA (for 3-NT) or 5% low-fat dry milk. Incubation with
the primary antibodies: mouse anti-Ras, 1:1000 (Millipore),
rabbit anti-3-NT, 1:500 (Millipore), mouse anti-neuronal
NOS, 1:500, mouse anti-endothelial NOS, 1:500, and rabbit
anti-iNOS, 1:500 (BD Transduction), in TBS-T containing
1% blocking solution was performed overnight, at 4C. After
rinsing with TBS-T, incubation with the appropriate HRP
secondary antibody conjugates (1:2000 in TBS-T containing
1% blocking solution) was performed at RT for 1 h. After
extensive washing in TBS-T followed by the incubation of
the membranes with the ClarityWestern ECL Substrate (Bio-
Rad Laboratories), immunoreactive bands were visualized in
the Molecular Imager ChemiDocTM XRS+ Imaging System
(Bio-Rad Laboratories). Image bands were analyzed with the
ImageLab software version 5.1 (Bio-Rad Laboratories).
Data analysis
Data are expressed as means – standard error of the mean.
Statistical significance was determined by using t-test for a
comparison of two population means or one-way or two-way
analysis of variance followed by Bonferroni’s or Dunnett’s
post-tests, as appropriate and indicated in the figure legends
and in the text. Differences were considered significant when
p < 0.05. The software used was GraphPad Prism 5.0
(GraphPad Software, La Jolla, CA).
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Abbreviations Used
# PSMs¼ number of peptide to spectrum matches
2-DE¼ two-dimensional electrophoresis
3-NT¼ 3-nitrotyrosine
ACN¼ acetonitrile
ANOVA¼ analysis of variance
bFGF¼ basic fibroblast growth factor
BSA¼ bovine serum albumin
CBMSO¼Centro de Biologı´a Molecular Severo Ochoa
CREB¼ cAMP response element-binding protein
CysSNO¼ S-nitroso-l-cysteine
D-MEM¼Dulbecco’s modified Eagle’s medium
DTT¼ dithiothreitol
EDTA¼ ethylenediaminetetraacetic acid
EdU¼ 5-ethynyl-2¢-deoxyuridine
EGF¼ epidermal growth factor
EGFR¼EGF receptor
eNOS¼ endothelial NOS
ERK¼ extracellular signal-regulated kinase
GAP¼GTPase activating protein
GEF¼ guanine nucleotide exchange factor
GFP¼ green fluorescent protein
GRB-2¼ growth factor receptor-bound protein 2
HRP¼ horseradish peroxidase
IAM¼ iodoacetamide
IgG¼ immunoglobulin G
iNOS¼ inducible nitric oxide synthase
KA¼ kainic acid
LC-MS/MS¼ liquid chromatography-tandem mass
spectrometry assay
m/z¼mass-to-charge ratio
MAPK¼mitogen-activated protein kinase
MEF2¼myocyte enhancer factor 2
MEK¼mitogen-activated protein kinase kinase
MH+¼ protonated monoisotopic mass
NEM¼N-ethylmaleimide
nNOS¼ neuronal NOS
NO¼ nitric oxide
NOS¼ nitric oxide synthases
NSC¼ neural stem cells
p27KIP1¼ cyclin-dependent kinase inhibitor 1
p90RSK¼ ribosomal S6 kinase
PAGE¼ polyacrylamide gel electrophoresis
PBS¼ phosphate-buffered saline
p-ERK¼ phospho-ERK
PVDF¼ polyvinylidene difluoride
RT¼ retention time
RT¼ room temperature
SAL¼ saline solution
SDS¼ sodium dodecyl sulfate
SEM¼ standard error of the mean
SNO¼ S-nitrosylation
SOS¼ son of sevenless
SVZ¼ subventricular zone
XCorr¼ raw cross-correlation score of the top PSM
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